FDA adds vision loss warning to Ozempic and Zepbound over NAION risk

The FDA said today that GLP-1 drugs may raise the risk of NAION, an eye condition causing sudden, painless and potentially permanent vision loss, and is adding a vision loss warning to Ozempic and Zepbound. Eli Lilly and Novo Nordisk must now add the warning to the drugs.

Detected & updated continuously · Source: Nebula